Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/179973
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jantus Lewintre, Eloisa | - |
dc.contributor.author | Massutí Sureda, Bartomeu | - |
dc.contributor.author | González Larriba, José Luis | - |
dc.contributor.author | Rodríguez Abreu, Delvys | - |
dc.contributor.author | Juan, Oscar | - |
dc.contributor.author | Blasco, Ana | - |
dc.contributor.author | Dómine, Manuel | - |
dc.contributor.author | Provencio Pulla, Mariano | - |
dc.contributor.author | Garde, Javier | - |
dc.contributor.author | Álvarez, Rosa | - |
dc.contributor.author | Maestu, Inmaculada | - |
dc.contributor.author | Pérez de Carrión, Ramón | - |
dc.contributor.author | Artal, Ángel | - |
dc.contributor.author | Rolfo, Christian | - |
dc.contributor.author | Castro Carpeño, Javier de | - |
dc.contributor.author | Guillot, Mónica | - |
dc.contributor.author | Oramas, Juana | - |
dc.contributor.author | Peñas, Ramón de las | - |
dc.contributor.author | Ferrera, Lioba | - |
dc.contributor.author | Martínez Banaclocha, Natividad | - |
dc.contributor.author | Serra, Òlbia | - |
dc.contributor.author | Rosell, Rafael | - |
dc.contributor.author | Camps, Carlos | - |
dc.date.accessioned | 2021-09-10T10:08:37Z | - |
dc.date.available | 2021-09-10T10:08:37Z | - |
dc.date.issued | 2021-07-26 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | http://hdl.handle.net/2445/179973 | - |
dc.description.abstract | Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes of patients with non-small-cell lung cancer treated with chemotherapy plus bevacizumab. We prospectively analyzed the relationship between VEGF-pathway components with both pathological and prognostic variables in response to chemotherapy plus bevacizumab in 168 patients with non-squamous non-small-cell lung cancer. Circulating levels of VEGF and VEGFR2 and expression of specific endothelial surface markers and single-nucleotide polymorphisms in VEGF-pathway genes were analyzed. The primary clinical endpoint was progression-free survival. Secondary endpoints included overall survival and objective tumor response. VEGFR-1 rs9582036 variants AA/AC were associated with increased progression-free survival (p = 0.012 and p = 0.035, respectively), and with improved overall survival (p = 0.019) with respect to CC allele. Patients with VEGF-A rs3025039 harboring allele TT had also reduced mortality risk (p = 0.049) compared with the CC allele. The VEGF-A rs833061 variant was found to be related with response to treatment, with 61.1% of patients harboring the CC allele achieving partial treatment response. High pre-treatment circulating levels of VEGF-A were associated with shorter progression-free survival (p = 0.036). In conclusion, in this prospective study, genetic variants in VEGFR-1 and VEGF-A and plasma levels of VEGF-A were associated with clinical benefit, progression-free survival, or overall survival in a cohort of advanced non-squamous non-small-cell lung cancer patients receiving chemotherapy plus antiangiogenic therapy. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media SA | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fonc.2021.695038 | - |
dc.relation.ispartof | Frontiers in Oncology, 2021, vol. 11 | - |
dc.relation.uri | https://doi.org/10.3389/fonc.2021.695038 | - |
dc.rights | cc by (c) Jantus Lewintre, Eloisa et al, 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Càncer de pulmó | - |
dc.subject.classification | Vasodilatadors | - |
dc.subject.other | Lung cancer | - |
dc.subject.other | Vasodilators | - |
dc.title | Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-09-10T07:18:10Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34381717 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fonc-11-695038.pdf | 1.09 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License